MedTrace Logo

Hepatic RFA Increases T Cell Infiltraion and PD-L1 Expression in Primary Colorecatl Cancer

NCT02475889 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 78

Last updated 2015-06-19

No results posted yet for this study

Summary

It has been shown that RFA induced systemic tumor antigen-specific T cell responses in human carcinoma. However, there are insufficient studies on the immune modulation of tumor microenviroment (TME) outside of the ablation zone. In order to study how RFA modifies TME in human cancer patients, investigators performed a retrospective study of a unique cohort of patients who suffered from synchronous CRCLM.

Conditions

Interventions

PROCEDURE

Hepatic RFA

Hepatic RFA was performed under guidace of ultrasonography (US) or computed tomography (CT) before primary tumor resection.

PROCEDURE

Primary tumor resection

Primary tumor resection were performed pre- or post-RFA for liver metastases.

Sponsors & Collaborators

  • The First People's Hospital of Changzhou

    lead OTHER

Principal Investigators

  • Changping Wu, M.D. · The First People's Hospital of Changzhou

Eligibility

Min Age
32 Years
Max Age
78 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2015-01-31
Completion
2015-01-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02475889 on ClinicalTrials.gov